Day: May 8, 2020

WALDORF, Md., May 08, 2020 (GLOBE NEWSWIRE) — Community Bank of the Chesapeake proudly supports community organizations through their Annual Casual for a Cause program. On behalf of their employees and the Community Bank team, they have pledged $20,000 in community giving. Now, more than ever, community support is important whether it is volunteering, supporting small businesses, or donating to the non-profit community.“We cannot show our appreciation enough for these organizations and the tireless work they do to support our communities. I am grateful to be a part of this community that feeds the hungry, shelters those in need, educates our youth and so much more,” said Jimmy Burke, President of Community Bank of the Chesapeake. “We look forward to our Casual for a Cause giving every year, but especially in these challenging times...

The category of the notice was changed to „Notifications on transactions concluded by managers of the companies“The company has received notifications of Invalda INVL about transactions in the Issuer’s securities (all notifications are in a single file).The person authorized to provide additional information:Real Estate Fund Manager of Management CompanyVytautas BakšinskasE-mail vytautas.baksinskas@invl.comAttachmentINVL Baltic Real Estate_notification_Invalda INVL-s0508

Pataisyta pranešimo kategorija į „Pranešimai apie vadovų sandorius“Pateikiame gautus AB „Invalda INVL“ pranešimus (visi pranešimai sudėti į vieną failą) dėl sandorių SUTNTIB „INVL Baltic Real Estate“ akcijomis.Asmuo, įgaliotas suteikti papildomą informaciją:Valdymo įmonės Nekilnojamojo turto fondo valdytojasVytautas BakšinskasEl.paštas vytautas.baksinskas@invl.comPriedasINVL Baltic Real Estate_vadovu sandoris_Invalda INVL-s0508

New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responsesSTARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional mRNA at all dosesSAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) — Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced new supportive preclinical data, providing evidence for an adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune response data from the Company’s COVID-19 vaccine program (LUNAR-COV19). These new results augment previously disclosed preclinical data demonstrating a strong antibody response (anti-spike protein IgG and 100% virus neutralization...

– Granted Approval by China Ministry of Commerce to Export Detection Kits Globally –– Obtained CE Certification by European Union –NEW YORK and SYDNEY, Australia, May 08, 2020 (GLOBE NEWSWIRE) — Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that its development of a medical solution using nanobody technology for the novel coronavirus (COVID-19), in collaboration with Tianjin University in China, has made a significant discovery of 24 types of nanobodies that can be used for the rapid detection and medical treatment of the SARS-CoV-2 virus.  After the screening of a library containing...

Boca Raton, FL, May 08, 2020 (GLOBE NEWSWIRE) — Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a global biomedical company that focuses on the orphan drug space announced today that Michael Grace, Ph.D. and Ronald Bordens, Ph.D. will be the first two members of the Company’s Scientific Advisory Board.“We are excited to report the formation of our new Scientific Advisory Board and we are grateful to Dr. Grace and Dr. Bordens for their commitment to the Company’s mission of aspiring to grow into an organization that fulfills the unmet needs of patients with rare diseases,” Paul M. Michaels, Interim CEO and Director said. Connectyx plans to build the Scientific Advisory Board to a five-member team with deep experience in a broad range of therapeutic areas. The Scientific Advisory...

UAB Ignitis Grupė, (hereinafter – the Company) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 600 000 000 EUR; ISIN codes XS1646530565; XS1853999313.On 8th of May, 2020, the Company received an information from the Ministry of Finance of the Republic of Lithuania, which is implementing the Company’s shareholder’s rights, that on the 8th of May, 2019, the Minister of Finance of the Republic of Lithuania passed an order with the decisions to:Approve the audited consolidated Annual Financial Statements of Ignitis Grupė for the year 2019 (attached);Allocate the profit (loss) of Ignitis Grupė for the year 2019 (attached);Approve the consolidated Annual Report of Ignitis Grupė for the year 2019 (attached).More information: Artūras Ketlerius,...

UAB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra UAB „Ignitis grupė“ išleistų obligacijų nominali vertė 600 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313.2020 m. gegužės 8 d. Bendrovė iš akcininko teises įgyvendinančios institucijos, Lietuvos Respublikos finansų ministerijos, gavo informaciją, kad Lietuvos Respublikos finansų ministras 2020 m. gegužės 8 d. įsakymu priėmė sprendimus, kuriais:Patvirtintas „Ignitis grupė“ 2019 metų audituotų konsoliduotųjų finansinių ataskaitų rinkinys (pridedama);Patvirtintas „Ignitis grupė“ 2019 metų pelno (nuostolių) paskirstymas (pridedama);Pritarta „Ignitis grupė“  2019 m. konsoliduotajam metiniam pranešimui (pridedama).Daugiau informacijos: Artūras Ketlerius, ryšių su visuomene vadovas, arturas.ketlerius@ignitis.lt,...

The company has received notifications of Invalda INVL about transactions in the Issuer’s securities (all notifications are in a single file).The person authorized to provide additional information:Real Estate Fund Manager of Management CompanyVytautas BakšinskasE-mail vytautas.baksinskas@invl.comAttachmentINVL Baltic Real Estate_notification_Invalda INVL-s0508

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) — Sutter Rock Capital Corp. (“Sutter Rock” or the “Company”) (Nasdaq:SSSS) today announced financial results for the quarter ended March 31, 2020.  Net assets totaled approximately $172.5 million, or $10.22 per share at March 31, 2020, as compared to $11.38 per share at December 31, 2019 and $10.75 per share at March 31, 2019.“Despite the ongoing impact of the COVID-19 outbreak, we believe our portfolio is well-positioned to weather the uncertainty and ultimately capitalize on several drivers of economic recovery,” said Mark Klein, President and Chief Executive Officer of Sutter Rock. “While overall market conditions contributed to a decline in NAV during the quarter, our strategic focus on identifying and investing in dynamic, high-growth, institutionally-backed private companies remains...